We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets
CTG 10.48+0.1%3:51 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: E_K_S10/10/2019 9:16:29 AM
1 Recommendation

Recommended By

   of 6850
UCB agrees to buy Ra Pharma for $2.5B
Oct. 10, 2019 6:51 AM ET|About: UCB SA (UCBJF)|By: Douglas W. House, SA News Editor

UCB SA ( OTCPK:UCBJF) has agreed to acquire Ra Pharmaceuticals (NASDAQ: RARX) for $48 per share in cash or $2.5B (€2.2B)($2.1B net of RARX cash).

UCB says the deal is consistent with its "Accelerate and Expand" strategy. In this case, it gains access to RA's zilucoplan, in Phase 3 development for myasthenia gravis (MG), complementing its own rozanolixizumab, also in late-stage development for MG.

Zilucoplan is also being evaluated in other complement-mediated disorders like ALS and immune-mediated necrotizing myopathy.

The transaction will not affect UCB's 2019 financial guidance. It will be dilutive to its mid-term earnings and will extend its mid-term goal of EBITDA/revenue of 31% out one year to 2022.

The deal should close by the end of Q1 2020.

RARX is up 106% premarket on light volume.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext